Beyond the Biomarker: Bridging Patient Voices and Precision Care in HER2-Mutant NSCLC

Please visit www.answersincme.com/CNW860 to participate, download slides and supporting materials, complete the post-test, and get a certificate. Presented by Stephen V. Liu, MD. In this activity, an expert in non–small-cell lung cancer (NSCLC) discusses the evolving patient-centered management of HER2-mutant NSCLC, focusing on the use of HER2-targeted TKIs. Upon completion of this activity, participants should be better able to: Describe how HER2-targeted TKIs may address the clinical needs for diverse patient populations with HER2-mutant NSCLC. Implement evidence-based molecular profiling to identify HER2 alterations in NSCLC. Evaluate the clinical evidence of current and emerging HER2-targeted treatments. Integrate shared decision-making strategies to align preferences for patients with HER2-mutant NSCLC.